The $125 million New York Genome Center (NYGC), set to start operations in the spring, unites 11 academic medical centers, with the shared goal of developing one of North America’s largest genomics facilities. Another goal for the genome center: close the longstanding gap in grant financing and infrastructure between New York and the nation’s top bioclusters, led by the San Francisco and Boston/Cambridge regions. “In many ways, New York missed the genomic era, and I don’t think anyone really realized how deep the problem was until they stopped to look at it,” Nancy J. Kelley, founding executive director of NYGC, told GEN. The center has raised about $100 million so far and has won support from corporate partners that include Roche and Illumina. What role do you see the NYGC playing in the growth of the city’s biotech cluster?

Poll Question:
How much do you think the New York Genome Center will succeed at growing the city’s biotech cluster?

A Great Deal


Not Much


Previous articleWashington Should Help Smaller Biotechs Gain International IP Protection According to Poll
Next articleTaiGen Acquires Global Rights to Warner Chilcott’s Late-Stage Antibiotic